A phase IV clinical trial to study the safety and immunogenicity of a single booster dose of BEs Tetanus Toxoid vaccine BETT administered to 18-50 year old healthy Indian adults of either gender.
Active, not recruitingCTRI/2009/091/000539
Biological E LimitedHealth Condition 1: Z23- Encounter for immunization
Target: 90Updated: 2021-11-24